Vajpayee Neerja, Burack Richard, Wang Dongliang, Hutchison Robert E, Gajra Ajeet
Department of Pathology, SUNY Upstate Medical University, Syracuse, NY.
Department of Pathology, University of Rochester Medical Center, School of Medicine and Dentistry, Rochester, NY.
Clin Lymphoma Myeloma Leuk. 2015 Mar;15(3):159-63. doi: 10.1016/j.clml.2014.09.010. Epub 2014 Oct 2.
The mammalian target of rapamycin (mTOR) pathway regulates many major cellular processes and is implicated in an increasing number of neoplasms, including lymphoma.
We correlated immunohistochemical expression of mTOR with germinal center and nongerminal center phenotype, B cell lymphoma-2 (bcl-2) and cellular homolog of the retroviral v-myconcogene (c-myc) expression, and International Prognostic Index (IPI) score in 31 patients with diffuse large B-cell lymphoma (DLBCL).
Virtually all patients in our study with high mTOR scores had a germinal center phenotype. Furthermore within the germinal center subgroup, patients with high mTOR scores were associated with higher IPI scores (P < .001).
Based on our results we propose that within the category of germinal center phenotype of DLBCL, mTOR expression might help identify a subset of patients with potentially more aggressive tumors who might benefit from use of targeted therapy using mTOR inhibitors.
雷帕霉素哺乳动物靶点（mTOR）通路调节许多主要细胞过程，并且与越来越多的肿瘤有关，包括淋巴瘤。
我们将31例弥漫性大B细胞淋巴瘤（DLBCL）患者的mTOR免疫组化表达与生发中心和非生发中心表型、B细胞淋巴瘤-2（bcl-2）和逆转录病毒v-myc癌基因细胞同源物（c-myc）表达以及国际预后指数（IPI）评分进行了关联分析。
在我们的研究中，几乎所有mTOR评分高的患者都具有生发中心表型。此外，在生发中心亚组中，mTOR评分高的患者与较高的IPI评分相关（P <.001）。
基于我们的结果，我们提出在DLBCL生发中心表型类别中，mTOR表达可能有助于识别一组肿瘤可能更具侵袭性的患者，这些患者可能受益于使用mTOR抑制剂的靶向治疗。
